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Introduction. Diabetic neuroosteoarthropathy (DNOAP) early symptoms are unspecific, mimicking general infectious symptoms
and rendering a diagnosis challenging. Consequently, unfavourable outcomes occur frequently, with recurrent foot ulceration,
infectious complications, and eventually amputation. Corneal confocal microscopy (CCM) of the subbasal nerve plexus (SNP) is
used to detect early peripheral neuropathy in diabetic patients without diabetic retinopathy. This pilot study was designed to
determine if specific SNP changes manifest in severe DNOAP in comparison to a healthy control group. Methods. This pilot
study utilized a matched-pair analysis to investigate SNP changes by in vivo CCM for 26 patients (mean patient age 63.7 years,
range 27 to 78) with severe DNOAP defined by condition after the need for reconstructive foot surgery (n = 13) and a healthy
control group (n = 13). Corneal nerve fibre length (CNFL), nerve fibre density (CNFD), nerve branch density (CNBD), average
weighted corneal nerve fibre thickness (CNFTh), nerve connecting points (CNCP), and average weighted corneal nerve fibre
tortuosity (CNFTo) were assessed as well as the general clinical status, diabetic status, and ophthalmologic basic criteria. Results.
In vivo CCM revealed significantly reduced SNP parameters in the DNOAP group for CNFL (p = 0 010), CNFD (p = 0 037),
CNBD (p = 0 049), and CNCP (p = 0 012) when compared to the healthy control group. Six patients (46%) of the DNOAP
group suffered from diabetic retinopathy and none of the control group. Conclusions. This pilot study revealed a rarefication of
SNP in all measured parameters in patients with severe DNOAP. We see a potential value of CCM providing a SNP-based
biomarker for early stages of DNOAP prior to the development of any foot deformities that needs to be evaluated in further
studies. This trial is registered with German Clinical Trials Register (DKRS) DRKS00007537.
1. Introduction
Diabetic neuroosteoarthropathy (DNOAP) of the foot is a
rare but devastating complication, characterized by a sterile
destruction of bones and joints accompanied by a diabetic
peripheral neuropathy that is estimated to affect 0.8%–8%
of the diabetic population [1]. The disease progression may
lead to a loss of osteoligamentous architecture with loss of
the plantigrade foot alignment [2, 3]. This progressive char-
acter of instability is associated with a serious impairment
of the quality of life and an estimated chance of up to 49%
to develop a recurrent ulceration with high risk for further
complications as infections and eventually the need for con-
secutive amputation [2, 3]. DNOAP patients with present
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ulcerations have a 12 times higher risk of amputation, com-
pared to those with ulcer-free feet [4]. The correct treatment
of DNOAP patients is still a matter of controversy. As the
current estimated annual limb amputation rate is 2.7%,
the main objective of any therapy is not only to lower the
occurrence of amputation [5] but also to provide the ability
to sustain a chronically infection- and ulcer-free foot to
maintain long-term walking independence [2, 6–8]. This
can be reached in approximately 60% of patients with planti-
grade foot alignment by applying nonoperative treatment
with total contact casting [2]. Anyhow, up to 40% of patients
require recasting, secondary minor surgery, or are placed on
prolonged disability [2, 6]. In severe DNOAP with loss of
plantigrade foot alignment and imminent complications
(e.g., ulceration), corrective arthrodesis techniques with
resection of the deformity and reconstruction arthrodesis
are often necessary [9–12].
Since early symptoms are unspecific, mimicking general
infectious symptoms in combination with reduced sensibility
due to polyneuropathy in diabetic patients, diagnosis of
DNOAP is challenging, with early stages frequently being
misdiagnosed as diabetic foot, infection, or oedema. Expert
consultation yielding a correct diagnosis is often delayed,
resulting in advanced disease, lost plantigrade foot align-
ment, and imminent complications. Until now, no diagnostic
tool or biomarkers identifying specific early symptoms have
been available to allow early diagnosis before onset of struc-
tural changes [9]. Therefore, there is an immediate need for
a noninvasive and reliable diagnostic approach to target
peripheral nerve damage primarily responsible for the devel-
opment of DNOAP in diabetic patients.
Previous ophthalmologic studies demonstrated a com-
plex relationship between the subbasal nerve plexus (SNP),
decreased corneal sensation, and the development of diabetic
retinopathy and neuropathy [13]. Currently, SNP analysis
is used as biomarkers in detecting early peripheral neurop-
athy in diabetic patients without diabetic retinopathy. In
vivo corneal confocal laser scanning microscopy (CCM),
a noninvasive corneal imaging technique, is frequently used
to analyse cellular structures of the layers of the cornea,
including small nerve fibres that compose the corneal SNP.
Further, CCM had successfully demonstrated morphological
changes of the SNP in corneal nerve fibre length, density, and
diameter in patients with diabetes and those with impaired
glucose tolerance directly associated with the progression of
diabetic retinopathy [14]. The neurotraumatic theory [15]
for pathogenesis of DNOAP is one of the two main theories
that attempts to explain the development of DNOAP. This
theory hypothesizes acute, subacute, or repetitive trauma as
a causative factor in the setting of absent protective sensation,
with the surrounding tissue responding with an acute-phase
proinflammatory reaction of cytokines (tumor necrosis fac-
tor-α, interleukin-1β, and interleukin-6) [16]. While this the-
ory does not explain all the changes seen in DNOAP,
neuropathy does seem to play a major role in its develop-
ment. Therefore, the aim of this pilot study is to determine
if specific SNP changes manifest in severe DNOAP. Those
might qualify as a biomarker to diagnose the disease at early
stages prior to the development of any foot deformities.
2. Methods
Participants (n = 26) for this clinical study include 13 ran-
domly chosen diabetic patients with severe DNOAP that
were age- and gender-matched with 13 healthy participants
(control group). Severe DNOAP was defined with the occur-
rence of bony deformities leading to a loss of the plantigrade
foot alignment, with subsequent surgical corrective osteot-
omy with reconstructive arthrodesis. CCM reconstruction
data were not available due to artefacts in two of the diabetic
patients. A detailed interview, review of patients’ medical
records, and clinical investigation in the Department of
Trauma, Hand and Reconstructive Surgery and Ophthalmo-
logical Department were conducted in January 2013 and
August 2014.
The study was conducted in strict accordance with the
Declaration of Helsinki and approved by the local Ethics
Committee of the Medical Faculty of the University of
Rostock (permit no. A 2012-0118). All participants were
informed prior the investigation by telephone and face-to-
face, and written consent was given.
2.1. Diabetical and General Clinical Status. Mean age of all
participants (19 males, 7 females) was 63.7± 11.6 years
(range 27–78) and was close to total mean between groups
(Charcot 61.1± 13.6 years (range 27–77), control 66.4± 8.8
years (range 51–78)). Medical condition of all patients was
assessed by review of patient-reported medical history and
review of patients’ charts. Clinical history of diabetes and
Charcot disease was recorded by secondary diagnosis, glycated
haemoglobin (HbA1c) levels, and basic patient characteristics.
Neuropathology was analysed bymonofilament testing adding
to tuning fork and reflex hammer examination.
2.2. CCM and Ophthalmological Status. All subjects com-
pleted a full ophthalmological evaluation by a single oph-
thalmologist which includes a slit lamp examination and
funduscopy. Corneal sensation measurements were obtained
by performing Cochet-Bonnet esthesiometry. CCM was
performed on unilateral eyes of all subjects. The used
CCM technique was developed by combining a Heidelberg
retina tomograph II (HRT II) with the Rostock cornea
module (RCM) (Heidelberg Engineering GmbH, Heidel-
berg, Germany), as previously described [17]. The HRTII/
RCM is equipped with immersion objective (Achroplan
63× 0.95W; Carl Zeiss Jena, Jena, Germany). For image
acquisition, a disposable cap made of PMMA (TomoCap,
Heidelberg Engineering GmbH) filled with a small amount
of the contact gel Vidisic (Dr. Gerhard Mann Chem.-Pharm.
Fabrik GmbH, Berlin, Germany) is put on the RCM lens. The
Vidisic gel is also used as a coupling medium between the
cornea and the TomoCap. Before image acquisition, the
examined eye was anesthetized with Proparakain 0.5% eye
drops (URSAPHARM, Saarbrücken, Germany). Using a
modified version of the HRT II software (oscillating volume
scan, operating mode), image stacks with an axial image dis-
tance of 0.5μm were acquired for each patient, with each
stack representing a partial volume of the patient’s cornea,
including the SNP. At least three scans were performed for
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each patient, with a total duration of the image acquisition
process of about 15 minutes. A specially developed image
processing software allows the detection and correction of
motion artefacts and ridge-like deformations. The result is a
motion-corrected image of the subbasal nerve plexus recon-
structed from each depth scan [18]. To create an expanded
field of view, a mosaic image is generated by all reconstructed
SNP images with common overlapping areas. Nerve struc-
tures and similar image features in the mosaic images were
subsequently segmented. Incorrectly segmented structures
(e.g., reconstruction artefacts, dendritic cells, and fibrotic tis-
sue) were removed based on their morphological properties
(size, elongation). In addition to the resulting image of the
segmented nerve fibres, the network of fibre centrelines was
finally calculated by thinning all segmented nerve fibres to a
width of one pixel. Both the segmentation image and the
thinned fibre network image formed the basis for the auto-
mated quantitative morphological and topological assess-
ment of the SNP. The following CCM parameters were
determined: corneal nerve fibre length (CNFL), defined as
the total length of all nerve fibres (mm/mm2); corneal nerve
fibre density (CNFD), defined as the number of nerve fibres
per mm2; corneal nerve branch density (CNBD), defined as
the number of branches per mm2; average weighted corneal
nerve fibre thickness (CNFTh), measured as mean thickness
perpendicular to the nerve fibre course (μm); corneal nerve
connecting points (CNCP), defined as the number of nerve
fibres crossing area boundary (connections/mm); and aver-
age weighted corneal nerve fibre tortuosity (CNFTo), reflect-
ing variability of nerve fibre directions and defined as total
absolute nerve fibre curvature. Each fibre segment termi-
nated by branching points, end points, and/or image borders
was considered a distinct nerve fibre for the calculation of the
above parameters. Weighting of single fibres was based on
their contribution to the length of the total fibre network;
for more details about the imaging and analysis process, see
Köhler et al. [19].
2.3. Statistical Analysis. Age and gender were determined to
be the most important factors for matching participants. All
data were processed in Excel 2010 (Microsoft Corporation,
Redmond, USA) and SPSS software package version 21.0
(SPSS, Chicago IL) and were used for statistical testing.
Descriptive statistics were computed for continuous and
categorical variables and are displayed as mean and stan-
dard deviations (SD). Kolmogorov-Smirnov test determined
normality of the tested variables, and either independent
t-test analyses or Mann-Whitney U test (nonnormal distri-
bution) was performed to analyse the differences in out-
comes between the two groups, with a significance level
defined at p = 0 05. The effect size was calculated accord-
ing to Cohens d and categorized into small (d =0.2–0.5),
medium (d =0.5–0.8), and large (d > 0.8) effect sizes.
3. Results
3.1. Diabetical and General Clinical Status. All but 2 patients
in the DNOAP group suffered from type 2 diabetes (n = 11);
the remaining patients were diagnosed with type 1 diabetes
(n = 2). Insulin dependency was manifest in 85% of patients.
The mean duration since onset of the diagnosis in type 2
diabetes patients was 18.5± 9.7 years. Six patients (46%)
suffered from 3 or more secondary diseases. All patients suf-
fered from diabetes-associated polyneuropathy; 4 patients
from a chronic renal insufficiency. Please see the detailed
basic patient characteristics in Table 1.
None of the patients in the control group had diabetes or
problems related to diabetes nor were any suffering from
more than 3 secondary diagnoses. One patient with chronic
urinary retention also suffered from chronic renal insuffi-
ciency, which likely developed after a stroke. None of the
control patients had severe foot deformities, and all were in
a healthy condition.
HbA1c levels in the DNOAP group were 8.2± 1.9% com-
pared to 5.4± 0.5% in the control group.
3.2. DNOAP. All patients in the DNOAP group were diag-
nosed with severe nonplantigrade Charcot foot deformity
and had undergone surgical corrective osteotomy with
reconstructive arthrodesis between November 2002 and
November 2014 (6 right feet and 7 left feet). Applying the
topographic classification of Sanders and Frykberg, a midfoot
affection type II and/or III, corresponding to the Lisfranc and
Chopart joint region, was causal in all but one foot. Further,
per Sanders/Fryberg type IV, an involvement of the subtalar
and talocalcaneal joints was visible in radiographs in 1 foot
solely and 2 feet additionally. All feet were operated during
the consolidation phase of Eichenholtz stage III. Surgical sta-
bilization of the medial column was performed using extra-
medullary implants (n = 11, 85%; thereof n = 7, 53%
angular stable plates) or intramedullary implants (n = 1,
8%) or a combination of both (n = 1, 8%). Stabilization of
the lateral column was performed using extramedullary
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implants in 11 feet (85%). Additionally, hindfoot arthrodesis
was performed in 1 foot (8%) via Ilizarov fixateur externe. A
representative case is shown in Figure 1.
DNOAP initial diagnosis was at mean 0.7± 0.9 years
(range 0–2) prior to reconstructive surgery. All but one
DNOAP patient had ulcer-free, stable feet at the time of oph-
thalmological evaluation. In one case, a secondary amputa-
tion of the lower leg was performed due to uncontrollable
infectious complications.
3.3. CCM and Ophthalmological Status. Six patients (46%) of
the DNOAP group were diagnosed with diabetic retinopa-
thy, 4 patients (31%) had received prior ocular treatment
(all pseudophakia), 2 patients (15%) were diagnosed with
glaucoma, and 3 patients (23%) were diagnosed with cata-
racts, compared to none of these conditions in the control
group. There were no significant differences of corneal sen-
sation between the two groups.
In vivo CCM revealed significant changes in SNP
morphology between the two groups (mean reconstructed
SNP area: control 0.25± 0.06mm2 (range 0.16–0.37), Char-
cot 0.19± 0.05mm2 (range 0.13–0.28)). Corneal nerve fibre
length (Charcot 13.08mm/mm2, control 20.03mm/mm2,
p = 0 010, d =1.09) and corneal nerve fibre density (Char-
cot 224.51/mm2, control 342.16/mm2, p = 0 037, d = 0 87)
were significantly reduced for the DNOAP group as dis-
played in Figure 2. Representative confocal images from both
study groups demonstrate readily visible SNP changes in
Figure 3.
The Charcot group showed significantly reduced cor-
neal nerve branch density (117.16/mm2) compared to the
control group (187.45/mm2 in the control group (p = 0 049,
d =0.81)). Analogously, the corneal nerve connecting points
(connections/mm) were highly significant with 49.75 con-
nections/mm2 in the Charcot group compared to 88.11 con-
nections/mm2 in the control group (p = 0 012, d =1.06) (see
Figure 4 for details). Table 2 shows values for average
weighted corneal nerve fibre thickness and average weighted
corneal nerve fibre tortuosity. There were no significant rela-
tionships between reported changes in CCM findings and
length of DNOAP or diabetic disease.
4. Discussion
Extensive research has focused on discovering the underlying
pathology responsible for DNOAP-specific acute, uncon-
trolled, localized inflammation that may lead to the develop-
ment of skeletal deformities that progress to the severe
rocker-bottom foot with a collapsed plantar arch. The onset
and the clinical presentation of DNOAP can mimic other
common pathologies and is therefore often misdiagnosed
or diagnosed at a later stage of the disease, causing inferior
patient outcome [20, 21]. Therefore, it is essential to differen-




Figure 1: Radiologic case series of a 56-year-old male patient with IDDM for 19 years and severe midfoot Charcot arthropathy-type Sanders/
Frykberg II/III on the left foot, with subluxation in the talocalcaneal and talonavicular joints. Initial diagnosis made in October 2013 after
trivial distortion of the upper ankle joint (a–c) bearing radiographs in lateral, anterior-posterior, and oblique views. Intra- and
extramedullary implants were used for reconstructive arthrodesis of the medial and lateral midfoot columns (d–f). Radiographs 6 months
after surgery reveal a loss of reduction and implant breakage, displaying a frequent problem in Charcot surgery (g–i).



































Figure 2: Corneal nerve fibre length defined as the total length of all nerve fibres (mm/mm2, p = 0 010) (a) and corneal nerve fibre density
defined as the number of nerve fibres per mm2 (p = 0 037) (b) in Charcot and control groups.
(a) (b) (c)
(d) (e) (f)
Figure 3: Confocal images demonstrating the morphology of SBN from 3 control subjects (a, b, c) and from 3 Charcot subjects (d, e, f).
(d, e, f) Exhibited readily visible changes with decrease in nerve fibers, decrease in nerve branches and connectivity, and abnormal








































Figure 4: Corneal nerve branch density defined as the number of branches per mm2 (p = 0 049) (a) and corneal nerve connecting points
defined as the number of nerve fibres crossing area boundary (p = 0 012) (b) in Charcot and control groups.
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from those who are not by using reliable methods of neu-
rological examinations. The most commonly used neurolog-
ical tools are capable of assessing large fibre neuropathy;
however, both large (A-fibres) and small (C-fibres) fibre neu-
ropathies are purported as possible causes of DNOAP [22].
Therefore, there is indication to study the density and
morphological changes of small fibres, which provide mostly
sensory and autonomic innervations, and to evaluate the pos-
sibility of early detection of DNOAP.
The cornea plays a pivotal role in the regulation of cor-
neal sensation, maintenance of epithelial integrity, prolifera-
tion, and promotion of wound healing and is the most
densely innervated tissue in the human body, supplied by ter-
minal branches of the ophthalmic division of trigeminal
nerve. Furthermore, it has been well established that the
quantity and morphology of the corneal nerve fibres can
reflect the status of diabetic polyneuropathy; therefore, the
assessment of SNP serves as a novel ophthalmic marker for
the detection of diabetic polyneuropathy [23, 24]. In vivo
CCM, a noninvasive corneal imaging technique, is a useful
and highly sensitive technique in the detection and assess-
ment of systemic diseases with peripheral neuropathy, such
as diabetes or polyneuropathic conditions. Increasing work
on quantifying diabetic neuropathy using CCM has demon-
strated that a significant reduction in corneal subbasal nerve
fibre density and an increase in nerve fibre tortuosity in dia-
betes are correlated with the stage or severity of peripheral
neuropathy [21–23]. In addition, CCM allows for the detec-
tion of early peripheral neuropathy, as the corneal nerve fibre
damage precedes the development of diabetic retinopathy
and impairment of corneal sensitivity [14]. As DNOAP is
generally one of the late complications of diabetes and is pri-
marily associated with diabetic polyneuropathy, assessment
of corneal subbasal nerves might provide useful insight into
the onset and progression of this condition.
While we are seeing an increase in the literature examin-
ing the pathophysiology of DNOAP, the work relating SNP
changes to the DNOAP remains limited. One such study by
Zhivov et al. [25] correlated diabetic foot syndrome and
corneal subbasal nerve plexus changes and demonstrated
decreased corneal sensation and decreased nerve fibre den-
sity in Congolese patients with type 2 diabetes with diabetic
retinopathy and advanced foot ulceration; however, none of
the patients suffered from DNOAP. The only CSLM study
on DNOAP known by the authors is a longitudinal observa-
tional one-case study by Dehghani et al. [26] that demon-
strated a rapid reduction of corneal nerve parameters prior
to the development of foot ulcerations and DNOAP. While
conventional measures of neuropathy did not deteriorate sig-
nificantly on this type 2 diabetes patient, CSLM showed
moderate to severe neuropathy at baseline followed by rapid
decline in corneal nerve fibre density, nerve branch density,
and fibre length over the duration of 7 years [26]. During this
period, the patient developed a foot ulcer and DNOAP with
the need for partial amputation. Similarly, our study demon-
strated a significant reduction in corneal nerve fibre length,
density, thickness, tortuosity, branch density, and connecting
points of SNP in the DNOAP group when compared to the
healthy control group. We rate these results as promising in
search for a DNOAP biomarker with the eye displaying an
ideal noninvasive diagnostic method. Anyhow, limitations
of the study are the solely survey of a collective with severe
DNOAP stages and the control group out of only healthy
patients. In future studies, the method will likely be applied
in comparing SNP changes in DNOAP patients with less
severe stages and to further subgroups from diabetic patients,
e.g., with diabetic neuropathy without DNOAP. Addition-
ally, long-term, longitudinal observations of SNP changes
in diabetic patients to discern specific changes prior to the
onset of DNOAP are of interest.
5. Conclusions
This pilot study revealed significant changes with large effect
size in all measured parameters of SNP for DNOAP when
compared to healthy controls with basically rarefication of
SNP. We see a potential value of CCM as noninvasive mea-
sure for diagnostics of DNOAP by qualifying SNP changes.
Further studies are needed to evaluate if SNP changes can
provide a biomarker to diagnose the disease at the early
stages, prior to the development of any foot deformities.
Data Availability
The data used to support the findings of this study are avail-
able from the corresponding author upon request.
Table 2: Average weighted corneal nerve fibre thickness (CNFTh),
measured as mean thickness perpendicular to the nerve fibre course
(μm) and average weighted corneal nerve fibre tortuosity (CNFTo),
reflecting variability of nerve fibre directions, defined as total
absolute nerve fibre curvature in both groups.
CNFTh
(mean value, in μm)
CNFTo
(mean value)
Charcot Control Charcot Control
2.25 2.31 1.30 2.07
2.19 2.41 1.32 1.29
2.27 2.25 1.50 1.49
2.27 2.20 2.51 1.45
2.28 2.23 1.82 1.19
2.34 2.18 1.54 1.60
2.21 2.33 1.20 3.00
2.29 2.38 1.41 1.33
2.30 2.32 1.33 1.36
2.28 2.32 1.43 1.66
2.20 2.28 1.25 1.33
2.20 2.35 1.94 1.32
2.16 2.27 1.96 1.61
∑ mean 2.25 2.30 1.58 1.60
SDV 0.05 0.07 0.38 0.48
Min 2.16 2.18 1.20 1.19
Max 2.34 2.41 2.51 3.00
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